BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sawyer EB, Edgeworth JA, Thomas C, Collinge J, Jackson GS. Preclinical detection of infectivity and disease-specific PrP in blood throughout the incubation period of prion disease. Sci Rep 2015;5:17742. [PMID: 26631638 DOI: 10.1038/srep17742] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Yakovleva O, Bett C, Pilant T, Asher DM, Gregori L. Abnormal prion protein, infectivity and neurofilament light-chain in blood of macaques with experimental variant Creutzfeldt-Jakob disease. J Gen Virol 2022;103. [PMID: 35816369 DOI: 10.1099/jgv.0.001764] [Reference Citation Analysis]
2 Nebie O, Buée L, Blum D, Burnouf T. Can the administration of platelet lysates to the brain help treat neurological disorders? Cell Mol Life Sci 2022;79:379. [PMID: 35750991 DOI: 10.1007/s00018-022-04397-w] [Reference Citation Analysis]
3 Moudjou M, Castille J, Passet B, Herzog L, Reine F, Vilotte JL, Rezaei H, Béringue V, Igel-Egalon A. Improving the Predictive Value of Prion Inactivation Validation Methods to Minimize the Risks of Iatrogenic Transmission With Medical Instruments. Front Bioeng Biotechnol 2020;8:591024. [PMID: 33335894 DOI: 10.3389/fbioe.2020.591024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Holec SAM, Block AJ, Bartz JC. The role of prion strain diversity in the development of successful therapeutic treatments. Prog Mol Biol Transl Sci 2020;175:77-119. [PMID: 32958242 DOI: 10.1016/bs.pmbts.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Eraña H, Charco JM, González-Miranda E, García-Martínez S, López-Moreno R, Pérez-Castro MA, Díaz-Domínguez CM, García-Salvador A, Castilla J. Detection of Pathognomonic Biomarker PrPSc and the Contribution of Cell Free-Amplification Techniques to the Diagnosis of Prion Diseases. Biomolecules 2020;10:E469. [PMID: 32204429 DOI: 10.3390/biom10030469] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
6 Llorens F, Villar-Piqué A, Schmitz M, Diaz-Lucena D, Wohlhage M, Hermann P, Goebel S, Schmidt I, Glatzel M, Hauw JJ, Sikorska B, Liberski PP, Riggert J, Ferrer I, Zerr I. Plasma total prion protein as a potential biomarker for neurodegenerative dementia: diagnostic accuracy in the spectrum of prion diseases. Neuropathol Appl Neurobiol 2020;46:240-54. [PMID: 31216593 DOI: 10.1111/nan.12573] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
7 Foliaki ST, Lewis V, Islam AMT, Ellett LJ, Senesi M, Finkelstein DI, Roberts B, Lawson VA, Adlard PA, Collins SJ. Early existence and biochemical evolution characterise acutely synaptotoxic PrPSc. PLoS Pathog 2019;15:e1007712. [PMID: 30970042 DOI: 10.1371/journal.ppat.1007712] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
8 Thompson AGB, Mead SH. Review: Fluid biomarkers in the human prion diseases. Mol Cell Neurosci 2019;97:81-92. [PMID: 30529227 DOI: 10.1016/j.mcn.2018.12.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
9 Seed CR, Hewitt PE, Dodd RY, Houston F, Cervenakova L. Creutzfeldt-Jakob disease and blood transfusion safety. Vox Sang 2018;113:220-31. [DOI: 10.1111/vox.12631] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
10 Charco JM, Eraña H, Venegas V, García-Martínez S, López-Moreno R, González-Miranda E, Pérez-Castro MÁ, Castilla J. Recombinant PrP and Its Contribution to Research on Transmissible Spongiform Encephalopathies. Pathogens 2017;6:E67. [PMID: 29240682 DOI: 10.3390/pathogens6040067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
11 Diack AB, Will RG, Manson JC. Public health risks from subclinical variant CJD. PLoS Pathog 2017;13:e1006642. [PMID: 29190276 DOI: 10.1371/journal.ppat.1006642] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
12 Kaufman SK, Thomas TL, Del Tredici K, Braak H, Diamond MI. Characterization of tau prion seeding activity and strains from formaldehyde-fixed tissue. Acta Neuropathol Commun 2017;5:41. [PMID: 28587664 DOI: 10.1186/s40478-017-0442-8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 12.4] [Reference Citation Analysis]
13 Brandner S, Jaunmuktane Z. Prion disease: experimental models and reality. Acta Neuropathol 2017;133:197-222. [PMID: 28084518 DOI: 10.1007/s00401-017-1670-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
14 Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases. Nature 2016;539:217-26. [PMID: 27830781 DOI: 10.1038/nature20415] [Cited by in Crossref: 151] [Cited by in F6Publishing: 156] [Article Influence: 25.2] [Reference Citation Analysis]
15 West Greenlee MH, Lind M, Kokemuller R, Mammadova N, Kondru N, Manne S, Smith J, Kanthasamy A, Greenlee J. Temporal Resolution of Misfolded Prion Protein Transport, Accumulation, Glial Activation, and Neuronal Death in the Retinas of Mice Inoculated with Scrapie. Am J Pathol 2016;186:2302-9. [PMID: 27521336 DOI: 10.1016/j.ajpath.2016.05.018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
16 Strømland Ø, Jakubec M, Furse S, Halskau Ø. Detection of misfolded protein aggregates from a clinical perspective. J Clin Transl Res 2016;2:11-26. [PMID: 30873457] [Reference Citation Analysis]